Cargando…

Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma

Rationale: The existence of primary and acquired drug resistance is the main obstacle for the effect of multi-kinase inhibitor sorafenib and regorafenib in advanced hepatocellular carcinoma (HCC). However, plenty of patients did not significantly benefit from sorafenib treatment and little is known...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Jing, Sui, Cheng-Jun, Wang, Dong-Fang, Lu, Xin-Yuan, Luo, Gui-Juan, Zhao, Qing, Lian, Qiu-Yu, Jeong, Seogsong, Lin, Xi-Meng, Zhu, Yan-Jing, Zheng, Bo, Wu, Rui, Wang, Qing, Liu, Xiao-Long, Liu, Jing-Feng, Xia, Qiang, Wu, Gang, Gu, Jin, Wang, Hong-Yang, Chen, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196302/ https://www.ncbi.nlm.nih.gov/pubmed/32373219 http://dx.doi.org/10.7150/thno.41616

Ejemplares similares

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Characterization of metabolic landscape in hepatocellular carcinoma
por: Wu, Jing, et al.
Publicado: (2021)

Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus
por: Zhang, Zi-Han, et al.
Publicado: (2017)

DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
por: Chen, Xin, et al.
Publicado: (2022)

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
por: Tian, Xinchen, et al.
Publicado: (2022)

Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma
por: Zhang, Qiang-Bo, et al.
Publicado: (2013)

Trajectory and Functional Analysis of PD‐1(high) CD4(+)CD8(+) T Cells in Hepatocellular Carcinoma by Single‐Cell Cytometry and Transcriptome Sequencing
por: Zheng, Bo, et al.
Publicado: (2020)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Exploration of Sorafenib Influences on Gene Expression of Hepatocellular Carcinoma
por: Wang, Huancheng, et al.
Publicado: (2020)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica
por: Liu, Zhu, et al.
Publicado: (2022)

Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma
por: Jeong, Seogsong, et al.
Publicado: (2016)

Identification of NOX4 as a New Biomarker in Hepatocellular Carcinoma and Its Effect on Sorafenib Therapy
por: Li, Hui-Zhou, et al.
Publicado: (2023)

Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Zheng, Liming, et al.
Publicado: (2021)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Correction: Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica
por: Liu, Zhu, et al.
Publicado: (2023)

The somatic mutation landscape of Chinese Colorectal Cancer
por: Ma, Rong, et al.
Publicado: (2020)

Combination of Metformin and Sorafenib Induces Ferroptosis of Hepatocellular Carcinoma Through p62-Keap1-Nrf2 Pathway
por: Tang, Kezhong, et al.
Publicado: (2022)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations
por: Yao, Song, et al.
Publicado: (2016)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor
por: Li, Jiaqi, et al.
Publicado: (2018)

The mutational landscape of hepatocellular carcinoma
por: Lee, Ju-Seog
Publicado: (2015)

The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma
por: Cheng, Chiung-Chi, et al.
Publicado: (2019)

CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma
por: Li, Bowen, et al.
Publicado: (2021)

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy
por: Zhou, Jing, et al.
Publicado: (2022)

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma
por: Shi, Yi, et al.
Publicado: (2021)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma
por: Zhou, Li, et al.
Publicado: (2022)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
por: Tang, Weiwei, et al.
Publicado: (2020)

High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients
por: Zhang, Xiaomin, et al.
Publicado: (2021)

LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells: LIMT contributes to sorafenib chemoresistance in HCC
por: Sun, Jing, et al.
Publicado: (2021)

Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations
por: Li, Jing, et al.
Publicado: (2016)

Landscape of gene mutation in Chinese thyroid cancer patients: Construction and validation of lymph node metastasis prediction model based on clinical features and gene mutation marker
por: Wei, Meng, et al.
Publicado: (2023)

Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
por: Meng, Xiao-Chun, et al.
Publicado: (2018)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
por: Zheng, Ning, et al.
Publicado: (2019)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1
por: Wang, Kai, et al.
Publicado: (2023)

Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study
por: Wang, Yizhuo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_21rv2is4cgnkicmsvcobed85v7